Spontaneous In Vitro Anti-Human Immunodeficiency Virus Type 1 Antibody Secretion By Peripheral Blood Mononuclear Cells Is Related To Disease Progression In Zidovudine-Treated Adults

Abstract
As part of a continuous search for surrogate markers of therapeutic efficacy in AIDS, spontaneous in vitro production by peripheral blood mononuclear cells of antibody to human immunodeficiency virus type 1 (HIV-1) was investigated in 50 HIV-I-infected adults. It was independent of CD4+ cell counts, p24 antigenemia, serum β2 -microglobulin concentration, and clinical status of the patients. The effect of zidovudine on this antibody secretion and the appearance of signs or symptoms ofHIV-1 disease progression were evaluated in 20 patients over 24 weeks. Anti-HIV1 antibody secretion decreased significantly (P = .002) as of the first month of zidovudine treatment only in the 13 HIV-I-infected patients without disease progression. This is earlier than the occurrence of variations in CD4+ cell count and serum β2 -microglobulin concentration. These results suggest that in vitro antibody production could be a surrogate marker for evaluation of the in vivo antiretroviral efficacy of zidovudine, even in p24 antigen-negative patients.

This publication has 0 references indexed in Scilit: